BioGaia has signed an agreement with Ferozsons Laboratories for the exclusive rights to sell probiotic drops and tablets in Pakistan. The products will be sold under the BioGaia brand and launch is planned for 2013.
Listed since 1960, Ferozsons is one of Pakistan's leading pharmaceutical companies with several market-leading brands in the fields of gastroenterology, cardiology and oncology. It is focused on medical marketing and has a large medical field force.
Both the BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain BioGaia’s patented and probiotic strain Lactobacillus reuteri Protectis. Today the drops are available in 52 countries and the tablets in 46 countries.
“We are pleased with the agreement with Ferozsons Laboratories. As Pakistan is the world’s sixth most populous country with a population of 187 million people, with a large proportion of children, the potential for our probiotic products should be good”, said Peter Rothschild, chief executive of BioGaia.